Chimeric Antigen Receptor T‐Cell Therapy: Potentially Nephrotoxic?



Acute Kidney Injury/chemically induced, Acute Kidney Injury/etiology, Receptors, Antigen, T‐Cell/therapeutic use, Chimeric Antigen


Introduction: Chimeric antigen receptor (CAR) T‐cell therapy is an effective new treatment for hematologic malignan‐ cies. In this study, we aimed to characterize the acute kidney injury (AKI) and electrolyte disorders among adults with refractory and relapsed haematological malignancies treated with CAR‐T therapy and explore clinical outcomes.

Methods: A retrospective, observational study was performed. Adult patients who received anti‐CD19 CAR‐T therapy between January 2019 and July 2022 were screened for inclusion.

Results: Among 41 patients receiving CAR T‐cell therapy, cytokine release syndrome and neurotoxicity rates occurred in 65.9% and 19.5%, respectively. AKI occurred in 6 patients (14.6%): 4 had stage 1 AKI and 2 developed stage 2 AKI, all re‐ lated to decreased kidney perfusion. Electrolyte abnormalities occurred in 65.9% and most of them were clinically mild.

Conclusion: In this study, the incidence of AKI was low, with a complete resolution in most cases by the end of follow‐up. Electrolyte abnormalities were common among recipients of CAR‐T, although of low severity.


Download data is not yet available.


Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev. 2016; 30: 157–67. doi: 10.1016/j. blre.2015.10.003.

Kanduri SR, Cheungpasitporn W, Thongprayoon C, Petnak T, Lin Y, Kovvuru K, et al. Systematic review of risk factors and incidence of acute kidney injury among patients treated with CAR‐T Cell therapies. Kidney Int Rep. 2021; 6: 1416–22. doi: 10.1016/j.ekir.2021.02.013.

June CH, Sadelain M. Chimeric antigen receptor therapy. New Engl J Med. 2018; 379: 64–73. doi: 10.1056/NEJMra1706169.

Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T‐cell therapy‐assessment and management of toxicities. Nat Rev Clin Oncol. 2018; 15: 47–62. doi: 10.1038/nrclinonc.2017.148.

Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR‐T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022; 13. doi:10.3389/fimmu.2022.927153.

Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021; 12. doi:10.1186/s13287‐020‐02128‐1.

Brudno JN, Kochenderfer JN. Recent advances in CAR T‐cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019; 34: 45–55. doi: 10.1016/j.blre.2018.11.002.

Jhaveri KD, Rosner MH. Chimeric antigen receptor T cell therapy and the kidney: What the nephrologist needs to know. Clin J Am Soc Nephrol. 2018;13:796‐8. doi: 10.2215/CJN.12871117.

Perazella MA, Shirali AC. Nephrotoxicity of cancer immunotherapies: past, present and future. J Am Soc Nephrol. 2018;29:2039‐52. doi: 10.1681/ASN.2018050488.

Gutgarts V, Jain T, Zheng J, Maloy MA, Ruiz JD, Pennisi M, et al. Acute kidney injury after CAR‐T cell therapy: low incidence and rapid recov‐ ery. Biol Blood Marrow Transplant. 2020;26:1071‐6. doi: 10.1016/j. bbmt.2020.02.012.

Gupta S, Seethapathy H, Strohbehn IA, Frigault MJ, O’Donnell EK, Jacobson CA, et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor t‐cell (CAR‐T) therapy for diffuse large b‐cell lymphoma. Am J Kidney Dis. 2020;76:63‐71. doi: 10.1053/j. ajkd.2019.10.011.

Farooqui N, Sy‐Go JPT, Miao J, Mehta R, Vaughan LE, Bennani NN, et al. Incidence and risk factors for acute kidney injury after chimeric antigen receptor T‐cell therapy. Mayo Clin Proc. 2022; 97: 1294–304. doi: 10.1016/j.mayocp.2022.05.018.

Ying Z, He T, Wang X, Zheng W, Lin N, Tu M, et al. Parallel comparison of 4‐1BB or CD28 co‐stimulated CD19‐targeted CAR‐T cells for b cell non‐Hodgkin’s lymphoma. Mol Ther Oncolytics. 2019;15:60‐68. doi: 10.1016/j.omto.2019.08.002.

Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long‐term Risk of Mortality and Other Adverse Outcomes After Acute Kidney Injury: A Systematic Review and Meta‐analysis. Am J Kidney Dis. 2009;53:961‐ ‐73. doi: 10.1053/j.ajkd.2008.11.034.

Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005;16:3365‐70. doi: 10.1681/ ASN.2004090740.






Original Article

How to Cite

Chimeric Antigen Receptor T‐Cell Therapy: Potentially Nephrotoxic?. (2024). Portuguese Kidney Journal, 38(1), 18-23.

Most read articles by the same author(s)

1 2 3 > >> 

Similar Articles

1-10 of 17

You may also start an advanced similarity search for this article.